Menu

Latest Pharma Insights



Regeneron Approval In Myasthenia Gravis Brings Two Firsts
From a 2019 partnership with Alnylam, Livsayis marks Regeneron’s first neurology launch and its first approved siRNA drug.
Scrip - November 19, 2026
Regulatory Attorneys Outline FDA’s Evolving Approach To Digital Health
Squire Patton Boggs attorneys said manufacturers must assess intended use, document regulatory decisions and reassess classifications as products and FDA policies evolve, even as 2026 FDA guidance gives wearables, clinical decision support software and AI tools more flexibility.
Medtech Insight - November 19, 2026
Sanofi May Have Its Eye On Insmed, But Can It Afford To Buy It?
M&A is a top priority for the French pharma, which is rumored to be considering an acquisition of Insmed, the developer of Brinsupri and Arikayce.
Scrip - November 19, 2026
Asia Deal Watch: Pfizer Gets Three Autoimmune CAR-T Candidates From Starna
Plus deals involving Tempest/Senlang, Kyorin/Edesa, Qyuns/Caldera, Hinova/Evommune, GC/Hanmi/BioMarin, Tanabe/Nippon Shinyaku, Nxera/Idorsia, Astellas/Audax and more.
Scrip - November 19, 2026
AbbVie Bispecifics Strategy Staying Alive With DISCO Deal
Deal Snapshot: German biotech DISCO Pharmaceuticals announced a partnership and option-to-license deal with the big pharma centered on bispecifics for hard-to-treat solid tumors.
Scrip - November 19, 2026
Teva CMO Hughes Departs After Orchestrating Pivot To Innovative Pharma
The company surprised investors with news that R&D head Eric Hughes will leave the company but said its R&D priorities remain unchanged.
Scrip - November 19, 2026
Cognito Leans On Mild Alzheimer’s Subgroup In FDA Push After Pivotal Trial Misses Endpoints
Cognito Therapeutics signaled it plans to try to work with the US FDA on regulatory authorization for its Spectris AD non-invasive Alzheimer’s treatment, citing slower decline in patients with mild Alzheimer’s. The study showed no treatment benefit for patients whose condition was more advanced.
Medtech Insight - November 19, 2026
Due Diligence Podcast: Why Are Reverse Mergers Increasing Despite Rising IPO Activity?
Biotech execs Matt Davidson and Sheila Gujrathi and attorney Mike Blankenship join Scrip’s Joseph Haas to discuss the uptick of reverse mergers in 2026 and the factors driving that trend.
Scrip - November 19, 2026
Sanofi Celebrates As Venglustat Finally Crosses The Line
The FDA has approved the French firm's GCS inhibitor, which will be marketed as Infilbray and is the first treatment for the neurological symptoms of type 3 Gaucher disease.
Scrip - November 19, 2026
People On The Move: Appointments At Karo, Haleon, Bayer Consumer Health
A round-up of the latest moves in Europe's consumer health sector: Karo Healthcare names CEO; Haleon appoints chief growth officer; Bayer gets new cluster head for Germany and Austria.
HBW Insight - November 19, 2026
How Does Novartis Plan To Grow Through A Second Round Of Patent Expirations?
Novartis growth guidance is 5% a year through 2031, from 5-6% from 2025 to 2030, as Kisqali loses US exclusivity. Peak sales guidance for three drugs rose to $18bn.
Scrip - November 19, 2026
Jefferies Healthcare Conference: Globus Targets Nevro Right-Sizing And Outcomes Improvements
Globus CFO Kyle Kline spoke about strategic plans for 2027 at the Jefferies Healthcare Conference, London, on Nov. 18.
Medtech Insight - November 19, 2026
Why FDA’s Home-Ventilator Product Code Undercounts A Thinning Market
Philips is barred from new US sales, Medtronic and Resmed have made their ventilators obsolete and Vyaire’s ventilator lines now belong to Zoll. There is only one company still winning 510(k) clearances under FDA’s dedicated home-ventilator product code.
Medtech Insight - November 19, 2026
OPPI Seeks RDP, Faster Clinical Trial Reforms To Attract Pharma R&D To India
OPPI is looking to secure policy changes that would encourage global drugmakers to expand their research centres and clinical development programs in India
Scrip - November 19, 2026
Viatris Expects Immediate Boost After Completing Pacira Acquisition
Viatris has completed its acquisition of Pacira BioSciences, pointing to an immediate additional sales contribution of as much as $100m that it expects to bring in by the end of this year.
Generics Bulletin - November 19, 2026
Sandoz Benefits From New Zealand Reliance Pathway To Rapidly Gain Paliperidone Approval
Under New Zealand’s new “rule of two” pathway, Sandoz has received approval for its paliperidone generic in just 25 working days. Regulator Medsafe says the approach saved around 10 months of assessment time and is already in discussions with other firms interested in using the expedited process.
Generics Bulletin - November 19, 2026
Biocon Celebrates Milestone First European Approval Via Streamlined Biosimilar Pathway
Biocon has celebrated the first biosimilar approval under the European Medicines Agency’s new tailored regulatory approach that does not typically require Phase III comparative efficacy studies. The firm’s Pebrilzo pertuzumab rival to Perjeta is set to hit the EU market early next year.
Generics Bulletin - November 19, 2026
Treehill’s Pashazadeh On China, The Funding Drought And Why Biotech’s Model Has To Change
Ali Pashazadeh of Treehill Partners tells In Vivo which of his public predictions on biotech financing, clinical development and China proved right, which didn’t, and what he expects over the next two years.
In Vivo - November 19, 2026
Tanabe Shuts Down NeuroDerm, Along With Approved Parkinson’s Drug
Decision resulted from “a comprehensive review of future strategy” and follows series of other divestment moves by Tanabe since Bain Capital acquisition.
Scrip - November 19, 2026
Machine Learning In Life Sciences: A Blueprint For Regulated AI Adoption
Industry benchmarks indicate that 70% of healthcare and life sciences organizations are actively using AI in 2026, and the adoption of generative AI and large language models (LLMs) has surged, underlining how these technologies have become core strategic imperatives.
In Vivo - November 19, 2026
Novartis Taps Taiwan’s OBI In Potential $2bn+ ADC Platform Alliance
Novartis signs deal to apply Taiwanese antibody-drug conjugate platform specialist's technologies in latest bid to create differentiated assets in crowded space.
Scrip - November 19, 2026
Senate Hemp Regulation Bill Increases THC Level To 1%, But Excludes Common Ingredients
Sens. Amy Klobuchar and Tim Sheehey introduce Hemp Guardrails Act to increase to 1% the limit for any THC in lawful hemp while excluding delta-8 and -10 and other THCs common in products.
HBW Insight - November 19, 2026
Coty’s Langan On Iconic Brands: ‘Protect What’s Timeless,’ Evolve The Rest
Kara Langan, the new head of Coty’s Consumer Beauty US business, shares her views on heritage brands, accessible beauty and what today’s shoppers want.
HBW Insight - November 19, 2026

Regeneron Approval In Myasthenia Gravis Brings Two Firsts
From a 2019 partnership with Alnylam, Livsayis marks Regeneron’s first neurology launch and its first approved siRNA drug.
Scrip - November 19, 2026
Sanofi May Have Its Eye On Insmed, But Can It Afford To Buy It?
M&A is a top priority for the French pharma, which is rumored to be considering an acquisition of Insmed, the developer of Brinsupri and Arikayce.
Scrip - November 19, 2026
Asia Deal Watch: Pfizer Gets Three Autoimmune CAR-T Candidates From Starna
Plus deals involving Tempest/Senlang, Kyorin/Edesa, Qyuns/Caldera, Hinova/Evommune, GC/Hanmi/BioMarin, Tanabe/Nippon Shinyaku, Nxera/Idorsia, Astellas/Audax and more.
Scrip - November 19, 2026
AbbVie Bispecifics Strategy Staying Alive With DISCO Deal
Deal Snapshot: German biotech DISCO Pharmaceuticals announced a partnership and option-to-license deal with the big pharma centered on bispecifics for hard-to-treat solid tumors.
Scrip - November 19, 2026
Teva CMO Hughes Departs After Orchestrating Pivot To Innovative Pharma
The company surprised investors with news that R&D head Eric Hughes will leave the company but said its R&D priorities remain unchanged.
Scrip - November 19, 2026
Due Diligence Podcast: Why Are Reverse Mergers Increasing Despite Rising IPO Activity?
Biotech execs Matt Davidson and Sheila Gujrathi and attorney Mike Blankenship join Scrip’s Joseph Haas to discuss the uptick of reverse mergers in 2026 and the factors driving that trend.
Scrip - November 19, 2026
Sanofi Celebrates As Venglustat Finally Crosses The Line
The FDA has approved the French firm's GCS inhibitor, which will be marketed as Infilbray and is the first treatment for the neurological symptoms of type 3 Gaucher disease.
Scrip - November 19, 2026
How Does Novartis Plan To Grow Through A Second Round Of Patent Expirations?
Novartis growth guidance is 5% a year through 2031, from 5-6% from 2025 to 2030, as Kisqali loses US exclusivity. Peak sales guidance for three drugs rose to $18bn.
Scrip - November 19, 2026
OPPI Seeks RDP, Faster Clinical Trial Reforms To Attract Pharma R&D To India
OPPI is looking to secure policy changes that would encourage global drugmakers to expand their research centres and clinical development programs in India
Scrip - November 19, 2026
Tanabe Shuts Down NeuroDerm, Along With Approved Parkinson’s Drug
Decision resulted from “a comprehensive review of future strategy” and follows series of other divestment moves by Tanabe since Bain Capital acquisition.
Scrip - November 19, 2026
Novartis Taps Taiwan’s OBI In Potential $2bn+ ADC Platform Alliance
Novartis signs deal to apply Taiwanese antibody-drug conjugate platform specialist's technologies in latest bid to create differentiated assets in crowded space.
Scrip - November 19, 2026

Regulatory Attorneys Outline FDA’s Evolving Approach To Digital Health
Squire Patton Boggs attorneys said manufacturers must assess intended use, document regulatory decisions and reassess classifications as products and FDA policies evolve, even as 2026 FDA guidance gives wearables, clinical decision support software and AI tools more flexibility.
Medtech Insight - November 19, 2026
Cognito Leans On Mild Alzheimer’s Subgroup In FDA Push After Pivotal Trial Misses Endpoints
Cognito Therapeutics signaled it plans to try to work with the US FDA on regulatory authorization for its Spectris AD non-invasive Alzheimer’s treatment, citing slower decline in patients with mild Alzheimer’s. The study showed no treatment benefit for patients whose condition was more advanced.
Medtech Insight - November 19, 2026
Jefferies Healthcare Conference: Globus Targets Nevro Right-Sizing And Outcomes Improvements
Globus CFO Kyle Kline spoke about strategic plans for 2027 at the Jefferies Healthcare Conference, London, on Nov. 18.
Medtech Insight - November 19, 2026
Why FDA’s Home-Ventilator Product Code Undercounts A Thinning Market
Philips is barred from new US sales, Medtronic and Resmed have made their ventilators obsolete and Vyaire’s ventilator lines now belong to Zoll. There is only one company still winning 510(k) clearances under FDA’s dedicated home-ventilator product code.
Medtech Insight - November 19, 2026

People On The Move: Appointments At Karo, Haleon, Bayer Consumer Health
A round-up of the latest moves in Europe's consumer health sector: Karo Healthcare names CEO; Haleon appoints chief growth officer; Bayer gets new cluster head for Germany and Austria.
HBW Insight - November 19, 2026
Senate Hemp Regulation Bill Increases THC Level To 1%, But Excludes Common Ingredients
Sens. Amy Klobuchar and Tim Sheehey introduce Hemp Guardrails Act to increase to 1% the limit for any THC in lawful hemp while excluding delta-8 and -10 and other THCs common in products.
HBW Insight - November 19, 2026
Coty’s Langan On Iconic Brands: ‘Protect What’s Timeless,’ Evolve The Rest
Kara Langan, the new head of Coty’s Consumer Beauty US business, shares her views on heritage brands, accessible beauty and what today’s shoppers want.
HBW Insight - November 19, 2026

Viatris Expects Immediate Boost After Completing Pacira Acquisition
Viatris has completed its acquisition of Pacira BioSciences, pointing to an immediate additional sales contribution of as much as $100m that it expects to bring in by the end of this year.
Generics Bulletin - November 19, 2026
Sandoz Benefits From New Zealand Reliance Pathway To Rapidly Gain Paliperidone Approval
Under New Zealand’s new “rule of two” pathway, Sandoz has received approval for its paliperidone generic in just 25 working days. Regulator Medsafe says the approach saved around 10 months of assessment time and is already in discussions with other firms interested in using the expedited process.
Generics Bulletin - November 19, 2026
Biocon Celebrates Milestone First European Approval Via Streamlined Biosimilar Pathway
Biocon has celebrated the first biosimilar approval under the European Medicines Agency’s new tailored regulatory approach that does not typically require Phase III comparative efficacy studies. The firm’s Pebrilzo pertuzumab rival to Perjeta is set to hit the EU market early next year.
Generics Bulletin - November 19, 2026

Treehill’s Pashazadeh On China, The Funding Drought And Why Biotech’s Model Has To Change
Ali Pashazadeh of Treehill Partners tells In Vivo which of his public predictions on biotech financing, clinical development and China proved right, which didn’t, and what he expects over the next two years.
In Vivo - November 19, 2026
Machine Learning In Life Sciences: A Blueprint For Regulated AI Adoption
Industry benchmarks indicate that 70% of healthcare and life sciences organizations are actively using AI in 2026, and the adoption of generative AI and large language models (LLMs) has surged, underlining how these technologies have become core strategic imperatives.
In Vivo - November 19, 2026